Today: 12 May 2026
RELX share price edges higher — what to watch before Thursday’s results
10 February 2026
1 min read

RELX share price edges higher — what to watch before Thursday’s results

London, Feb 10, 2026, 08:13 GMT — Regular session

  • RELX shares picked up in early London trading, snapping back after a tough stretch.
  • The next real mover: full-year results, expected Feb. 12.
  • Legal and data stocks are still wrestling with AI-driven volatility. That overhang hasn’t gone anywhere.

Shares of RELX PLC (REL.L) climbed 1.2% to 2,158 pence in early Tuesday trading in London, after ending Monday at 2,133 pence. So far, the stock has traded between 2,112 and 2,162 pence on the day—hovering just above the low end of its 52-week range, which spans from 2,112 to 4,205.

Investors remain jittery ahead of the company’s annual results, watching closely for any new take on generative AI and its potential impact on legal and scientific information markets. Last week, RELX and other data-driven names took a hit after Anthropic rolled out plug-ins for its Claude Cowork agent, stoking fresh fears around disruption in professional services.

RELX plans to report full-year numbers for 2025 on Feb. 12, according to its financial calendar. With the sector’s tone shifting fast, traders are expected to zero in on the company’s guidance just as much as the headline figures.

The mood out there has moved from outright panic to a more selective look at what’s left, though it’s far from uniform. “You’ve a sharply oversold market where a little bit of good news can go a long way,” said Keith Lerner, chief investment officer at Truist Advisory Services, following Monday’s rebound in U.S. tech and software stocks. Reuters

Even so, it’s a tangled picture. Software and services names have trailed the S&P 500 by almost 24 percentage points in just the last three months—approaching records for underperformance, Reuters said Monday.

RELX, a major player on London’s blue-chip index, is known for its information-based analytics and decision tools. Erik Engstrom, according to Reuters data, leads as chief executive. The company operates across several segments: legal, risk, scientific, and exhibitions.

The buyback pace at RELX hasn’t let up. On Feb. 6, it disclosed the purchase of 465,361 shares via UBS on the London Stock Exchange, pushing its total bought back since Jan. 2 to 8.84 million shares. The shares end up in treasury.

AI risk remains the sticking point, and it’s a double-edged sword. Last week, Reuters noted that investors are rushing to hedge portfolios, with the pace of AI progress clouding both valuations and longer-term business outlooks — making it tough for stocks to catch a break, even if price swings turn favorable in the short run.

All eyes on Thursday, when RELX is set to deliver its results and talk to investors. Webcast info for its 2025 results is now available on the investor website.

Stock Market Today

  • Wall Street Slides as AI Stocks Falter and Oil Prices Rise Amid Iran Conflict
    May 12, 2026, 5:23 PM EDT. Wall Street paused its record-setting rally as AI stocks declined and oil prices climbed amid tensions with Iran. The S&P 500 dropped 0.2% from its previous high, while the Nasdaq slipped 0.7%. Dow Jones Industrial Average rose slightly by 56 points. Significant losses hit chipmakers: Intel fell 6.8%, Micron Technology 3.6%, trimming strong year-to-date gains. South Korea's Kospi also dropped 2.3%, spooked by potential AI profit redistribution. Brent crude surged 3.4% to $107.77 a barrel due to Strait of Hormuz restrictions from the Iran war. Rising oil costs worsened U.S. inflation, surpassing forecasts, with Treasury yields climbing to 4.45%. Investors anticipate the Federal Reserve may maintain or hike interest rates amid persistent inflation concerns.

Latest article

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

12 May 2026
Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

12 May 2026
UnitedHealth shares climbed 3.1% to $396.45 Tuesday after unveiling a new Optum Rx fee-based pricing model and raising 2026 profit guidance. The company reported Q1 revenue of $111.7 billion and adjusted earnings of $7.23 per share. Management said fundamentals are improving but described the turnaround as ongoing. Investors responded to both the PBM overhaul and stronger earnings outlook.
BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

BuzzFeed Stock Nearly Doubles as Byron Allen Deal Buys Time, Not a Clean Turnaround

12 May 2026
BuzzFeed shares jumped 97% to about $1.44 Tuesday after Byron Allen’s family office agreed to buy 40 million new shares at $3 each, securing 52% control. Only $20 million is due in cash at closing, with the rest as a five-year promissory note. BuzzFeed reported Q1 revenue down 12.4% to $31.6 million and a net loss of $15.1 million. The company warned of “substantial doubt” about its ability to continue operating.
Amphenol stock jumps 6% as insider buy and board succession put APH back in focus
Previous Story

Amphenol stock jumps 6% as insider buy and board succession put APH back in focus

Oracle stock snaps back after OpenAI upgrade call — $50 billion fundraising looms
Next Story

Oracle stock snaps back after OpenAI upgrade call — $50 billion fundraising looms

Go toTop